

**32<sup>nd</sup> Annual Cancer Progress Conference, May 4<sup>th</sup> – 6<sup>th</sup> 2021**May 4, 2021**9:00 – 9:15 am****Opening Remarks**

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**9:15 – 10:00 am****Keynote: Engineering the Future: Next Gen Platforms in Oncology**

**Speaker:** Daniel S Chen, MD, PhD, Chief Medical Officer, IGM Biosciences

**10:15 – 11:30 am****Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors**

**Moderator:** Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting and James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Neil Brewis, PhD, Chief Scientific Officer, F-star Therapeutics
- Michael A Curran, PhD, Associate Professor, Dept. of Immunology  
Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center,  
Department of Immunology, Division of Basic Sciences
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics
- Emmett Schmidt, MD, PhD, Associate Vice President, Clinical Oncology & Lead, External  
Collaborations, Merck Research Laboratories

**11:45 am – 1:00 pm****Multifunctional Soluble Biologics: Binders, Binders Everywhere**

**Moderator:** James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Philip Bland-Ward, PhD, Chief Development Officer, Crescendo Biologics Ltd
- Alicia Chung, PhD, Corporate Development, Amphivena Therapeutics Inc
- Eliot Forster, BSc, PhD, MBA, FRSA, Chief Executive Officer, F-star Therapeutics
- Valerie Odegard, PhD, CSO, Silverback Therapeutics
- Taylor H. Schreiber, MD, Ph.D, Chief Executive Officer Shattuck Labs, Inc

**1:00 - 1:30 pm****Break for Lunch**

1:30 – 2:45 pm

### Tumor Agnostic Development

**Moderator:** Richard L. Schilsky, M.D., FACP, FSCT, FASCO, EVP and CMO, American Society of Clinical Oncology Association for Clinical Oncology

**Panelists:**

- Julie R. Gralow, MD, FACP, FASCO, professor of medical oncology and director of breast medical oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, and (CMO) of ASCO
- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research
- Mark Pegram, MD, Professor of Medical Oncology, Stanford Comprehensive Cancer Institute, Stanford University

3:00 – 4:15 pm

### Accelerated Development Paths

**Moderator:** Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research

**Panelists:**

- Professor Paul Workman, Chief Executive and President, The Institute of Cancer Research, London
- Ralph E. Parchment, PhD, Managing Director, DCTD Program in Pharmacodynamic Biomarkers, NCI

4:30 – 5:45 pm

### Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

**Moderator:** Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Nicholas A. Boyle, PhD, MBA, CEO, Abintus Bio
- Mary Haak-Frendscho, PhD, President & CEO, Spotlight Therapeutics
- Stephan Matthias, MD PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center
- Ulrik Nielsen, PhD, CEO, Tidal Therapeutics

5:45 pm **Day 1 Cancer Progress 2021 Conference Conclude**

**May 5, 2021**

9:00 – 9:15 am **Opening Remarks: Review of Day 1**

Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

9:15- – 10:00 am **Keynote Address: Title TBD**

**Speaker:** Katy Rezvani, MD, PhD, Principal Investigator, Professor, Stem Cell Transplantation & Cellular Therapy Department, MD Anderson Cancer Center

10:15- 11:30 am **Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists**

- Jason B. Litten, MD, Chief Medical Officer, Artiva Biotherapeutics, Inc., Artiva Biotherapeutics
- Annemarie Moseley, MD PhD, CEO, Sandhill Therapeutics
- Kelly Page, Global Head of Cell Therapy Commercialization of Cell Therapy Commercialization, Takeda
- Alan Trounson, MSc, PhD, CEO and Executive Director Cartherics
- Kurt Gunter, MD, Chief Medical Officer,kuur

11:45- 1:00 pm **Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Greg Block, PhD, SVP Corporate Development, Notch Therapeutics
- Rachel Haurwitz, PhD, Chief Executive Officer and Founder Caribou Biosciences, Inc.
- Sandy Hayes, Adicet/resTORbio
- Ajla Hrle, PhD, Director, Head of Strategic Alliances, Immatix Biotechnologies

1:00 – 1:30 pm **Break for Lunch**

1:30 – 2:45 pm

**Cell Therapy in Solid Tumors: Freedom of the Open Road**

**Moderator:** Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Sharon Benzeno, SVP, Drug Discovery, Adaptive Biotechnologies Corp.
- John Delyani, PhD VP, Corporate Development, Tminuty Therapeutics Inc
- Mythili Koneru, MD, PhD, Chief Medical Officer, Marker Therapeutics
- Peter Sandor, MD, MBA, Head of Oncology TA Marketing Strategy, Astellas
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune **LLC**
- Paul Wotton, PhD, CEO, Obsidian Therapeutics, Inc.

3:00- 4:15 pm

**Validating New Platforms: Clinical Pain, Commercial Gain**

**Moderator:** Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Robert Ang, MD, MBA, President & CEO, Vor Bio Pharm
- Debora Barton, MD, Chief Medical Officer, Carisma Therapeutics Inc.
- Lawrence Lamb, PhD, Scientific Co-Founder & Chief Scientific Officer, in8bio
- Jan ter Meulen, MD, PhD CSO, Obsidian Therapeutics, Inc.
- Dan Shoemaker, PhD, Chief Scientific Officer, Fate
- Gracell Biotechnologies, TBD

4:30-5:45 pm

**Counterpoint to Over-engineering: Bauhaus Minimalism in an Era of More Opulent T-cell Architecture**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Keith Bahjat, Sr Director Science, Cell Therapy Center of Excellence, Astellas
- Frank Borriello, MD, PhD, Founder & Chief Executive Officer, Alloplex Biotherapeutics
- Sabine Chlosta, MD, Chief Medical Officer, Triumvera
- Kimberly Noonan, PhD, Founder, EVP & Chief Scientific Officer WindMIL
- Paul D. Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics
- Immatics, TBD

## Day 2 Cancer Progress 2021 Conference Concludes

**May 6, 2021**

**8:15 – 8:30 am**      **Opening Remarks: Review of Day 2**

**8:30 – 9:45 am**      **China Panel**

**Moderator:** James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Guillaume Vignon, PhD, Senior Vice President, Business Development, BeiGene

**10:00- 11:15 am**      **Investing in the *Emerald City* of Oncology Innovation: Platforms & Modalities & Targets, Oh My!**

**Moderator:** Mark Simon, Partner and Co-Founder, Torrey

**Panelists:**

- Margarita Chavez, JD, Managing Director, AbbVie Ventures (tentative)
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Maha Katabi, PhD, CFA , General Partner, Sofinnova Investments
- Carolyn Ng, Director, Vertex Ventures
- Anna Turetsky, Principal, Venture Investments, The Mark Foundation

**11:30 am - 12:45 pm**      **Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML**

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**

- Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
- Lee Greenberger, MD, PhD, SVP & CSO, Leukemia & Lymphoma Society
- Daniel A Pollyea, MD MS, Associate Professor of Medicine, Division of Hematology, University of Colorado School of Medicine

12:45- 1:15 pm

**Break for Lunch**

1:30 - 2:45 pm

**Let's Make a Deal in Oncology: What's Behind the Doors & Who Has the Keys?**

**Moderator:** Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

**Panelists:**

- Christopher Mortko, Director and Oncology Search & Evaluation Lead, Merck & Co., Inc
- Marianne De Backer, PhD, MBA, EVP, Global Head Strategy and Business Development (CBO), Bayer (Tentative)
- Peter Sandor, MD, MBA, Head of Oncology TA Marketing Strategy, Astellas
- Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen

3:00- 4:15 pm

**Value Panel**

**Moderators:** Ed Saltzman, Executive Chairman, Cello Heath BioConsulting

**Panelists:**

- Ron Akehurst, Chairman, BresMed
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, VP and CIO, ADVI Health
- Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center

4:30 – 5:30pm

**Battle of the Modalities- The sequel**

- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
- James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting, previously Defined Health
- Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health
- Joel S. Sandler, PhD, Principal, Cello Health BioConsulting, previously Defined Health

**Cancer Progress 2021 Conference Concludes**